Stockscreener 앱 받기
0.8796
0.70%
-0.0062
시간 외 거래:
.87
-0.0096
-1.09%
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%Post-Earnings Drift - newsline.com
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - Investing News Network
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Clinical PipelinePre-Announcement Alert - newsline.com
RNXT Maintains Buy Rating by Ascendiant Capital -- Price Target Raised to $14.00 - GuruFocus
New chemotherapy delivery method scores FDA orphan drug status - Rare Cancer News
RNXT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances TrialsEarnings Preview - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Volatility Term Structure - The Legal Advocate
RenovoRx (RNXT) Advances 6.2% as Momentum Builds Toward ResistanceCall Spread Alert - The Legal Advocate
RenovoRx receives FDA orphan drug designation for oxaliplatin - Investing.com UK
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - Investing News Network
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com - Investing.com Australia
RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer - marketscreener.com
RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer - TradingView
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer - Stock Titan
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx reports pharmacokinetic data from pancreatic trial By Investing.com - Investing.com Nigeria
RenovoRx reports pharmacokinetic data from pancreatic trial - Investing.com
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - The Manila Times
Pancreatic cancer study tests drug delivery that may cut side effects - Stock Titan
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - newsline.com
RenovoRx Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineEPS Estimate Trend - Newser
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss; Stock Holds SteadyCrowd Stock Picks - Newser
RenovoRx Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues Clinical DevelopmentNet Income Trends - Newser
RenovoRx Inc. (RNXT) Hovers Near Support as Thin Trading PersistsExpert Momentum Signals - Newser
RenovoRx (RNXT) Slides to $0.88, Nearing Critical SupportRetail Driven Moves - Newser
RenovoRx CFO Mark Voll buys $19,690 in common stock By Investing.com - Investing.com Canada
RenovoRx CFO Mark Voll buys $19,690 in common stock - Investing.com India
RenovoRx (RNXT) Q1 2026 Results Trail Estimates: A Deeper LookGuidance Accuracy Score - Newser
RenovoRx (RNXT) CFO adds 25,000 shares, lifting direct stake to 142,380 - Stock Titan
RNXT: Targeted chemo delivery platform drives revenue growth and nears key clinical milestones - TradingView
RNXT: Targeted drug delivery platform drives revenue growth and nears key clinical milestones - TradingView
RenovoRx (RNXT) Q1 2026 Results Miss Estimates — EPS $-0.09 vs $-0.08Working Capital - Newser
RenovoRx Earnings Call Signals Commercial Inflection - TipRanks
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th - Investing News Network
1.27%
1.43%
자본화:
|
볼륨(24시간):